Prostate cancer patients with inherited BRCA2 mutations have a very aggressive disease, with higher grade, advanced stage at diagnosis and poor survival [14,15,16,17,18,19,20], making a priority the development of novel therapeutic strategies for these patients. This evidence concerns the gene BRCA2 and prostate cancer.